Kudos to @virtuahealth.bsky.social for enrolling their first patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. Learn more: bit.ly/pre1702-study
November 11, 2025 at 9:07 PM
Kudos to @virtuahealth.bsky.social for enrolling their first patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. Learn more: bit.ly/pre1702-study
Russian pharmaceutical company Axelfarm retained their patent for the production of drugs with osimertinib which is used to treat lung cancer. The challenge was from AstraZeneca which holds the patent on a drug with the substance.
www.kommersant.ru/doc/8194633
www.kommersant.ru/doc/8194633
Лекарству прописали патент
«Аксельфарм» удалось сохранить права на препарат от рака легких
www.kommersant.ru
November 11, 2025 at 7:29 PM
Russian pharmaceutical company Axelfarm retained their patent for the production of drugs with osimertinib which is used to treat lung cancer. The challenge was from AstraZeneca which holds the patent on a drug with the substance.
www.kommersant.ru/doc/8194633
www.kommersant.ru/doc/8194633
Amivantamab-Lazertinib Surpasses Osimertinib, Boosts Overall Survival to 60% in Untreated Patients After 37.8 Months
by Yang JC, Lu S (...) Cho BC et 53 al. in N Engl J Med #MedSky
👉 get more here
📖 read the article: https://www.nejm.org/doi/10.1056/NEJMoa2503001
by Yang JC, Lu S (...) Cho BC et 53 al. in N Engl J Med #MedSky
👉 get more here
📖 read the article: https://www.nejm.org/doi/10.1056/NEJMoa2503001
November 8, 2025 at 6:37 PM
Amivantamab-Lazertinib Surpasses Osimertinib, Boosts Overall Survival to 60% in Untreated Patients After 37.8 Months
by Yang JC, Lu S (...) Cho BC et 53 al. in N Engl J Med #MedSky
👉 get more here
📖 read the article: https://www.nejm.org/doi/10.1056/NEJMoa2503001
by Yang JC, Lu S (...) Cho BC et 53 al. in N Engl J Med #MedSky
👉 get more here
📖 read the article: https://www.nejm.org/doi/10.1056/NEJMoa2503001
Yale Study Sheds Light on Cellular Resistance to Osimertinib in Adenocarcinoma @yalecancer.bsky.social #oncology
www.onclive.com/view/yale-st...
www.onclive.com/view/yale-st...
Yale Study Sheds Light on Cellular Resistance to Osimertinib in Adenocarcinoma | OncLive
Protein METTL7A plays key role in resistance to drugs targeting EGFR-mutant lung adenocarcinoma.
www.onclive.com
November 7, 2025 at 8:28 PM
Yale Study Sheds Light on Cellular Resistance to Osimertinib in Adenocarcinoma @yalecancer.bsky.social #oncology
www.onclive.com/view/yale-st...
www.onclive.com/view/yale-st...
Great work to ProHealth Care for enrolling their first patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. More: bit.ly/4hyZUue #LCSM
Spotlight on Real-World Data Capture: The PrE1702 Registry Study in Lung Cancer
This major new initiative is a unique opportunity for researchers and patients to help build an important real-world data registry of patients with EGFR-mutated non-small cell lung cancer
bit.ly
November 5, 2025 at 2:08 PM
Great work to ProHealth Care for enrolling their first patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. More: bit.ly/4hyZUue #LCSM
New findings that adding chemotherapy to osimertinib (Tagrisso) for advanced EGFR-positive non-small cell lung cancer may help clarify options for first-line treatment. Read more in Cancer Today. buff.ly/7zkmjKf
November 4, 2025 at 3:42 PM
New findings that adding chemotherapy to osimertinib (Tagrisso) for advanced EGFR-positive non-small cell lung cancer may help clarify options for first-line treatment. Read more in Cancer Today. buff.ly/7zkmjKf
In advanced non–small-cell lung cancer with 𝘌𝘎𝘍𝘙 mutations, amivantamab–lazertinib led to longer overall survival than osimertinib but was associated with an increased risk of adverse events of grade 3 or higher. Full MARIPOSA phase 3 trial results and Research Summary: nej.md/4p6j53k
November 3, 2025 at 2:02 PM
In advanced non–small-cell lung cancer with 𝘌𝘎𝘍𝘙 mutations, amivantamab–lazertinib led to longer overall survival than osimertinib but was associated with an increased risk of adverse events of grade 3 or higher. Full MARIPOSA phase 3 trial results and Research Summary: nej.md/4p6j53k
Step 3：財務負擔
• Osimertinib + 化療：健保給付，財務負擔低。
• Amivantamab + Lazertinib：目前需自費，財務負擔高。
🎯 臨床對照表
🗝️ 給病人和家屬的淺白說法
• 單藥：簡單、負擔小，但癌細胞可能較快找到「後門」。
• 加化療：健保給付，效果更好，像是「鎖門+清掃隊」。
• 抗體+TKI：效果亮眼，但需自費，像是「鎖大門+後門」，但要付出更多資源。
• Osimertinib + 化療：健保給付，財務負擔低。
• Amivantamab + Lazertinib：目前需自費，財務負擔高。
🎯 臨床對照表
🗝️ 給病人和家屬的淺白說法
• 單藥：簡單、負擔小，但癌細胞可能較快找到「後門」。
• 加化療：健保給付，效果更好，像是「鎖門+清掃隊」。
• 抗體+TKI：效果亮眼，但需自費，像是「鎖大門+後門」，但要付出更多資源。
November 3, 2025 at 1:12 PM
Step 3：財務負擔
• Osimertinib + 化療：健保給付，財務負擔低。
• Amivantamab + Lazertinib：目前需自費，財務負擔高。
🎯 臨床對照表
🗝️ 給病人和家屬的淺白說法
• 單藥：簡單、負擔小，但癌細胞可能較快找到「後門」。
• 加化療：健保給付，效果更好，像是「鎖門+清掃隊」。
• 抗體+TKI：效果亮眼，但需自費，像是「鎖大門+後門」，但要付出更多資源。
• Osimertinib + 化療：健保給付，財務負擔低。
• Amivantamab + Lazertinib：目前需自費，財務負擔高。
🎯 臨床對照表
🗝️ 給病人和家屬的淺白說法
• 單藥：簡單、負擔小，但癌細胞可能較快找到「後門」。
• 加化療：健保給付，效果更好，像是「鎖門+清掃隊」。
• 抗體+TKI：效果亮眼，但需自費，像是「鎖大門+後門」，但要付出更多資源。
肺腺癌EGFR突變的決策流程
在台灣第三代 EGFR TKI（Osimertinib）合併化療有健保給付，因此「財務負擔」這個選項上相對不是考慮重點；反而副作用、基因型、年齡才是關鍵。
🔄 決策流程
Step 1：確認基因型
• Exon 19 deletion → 對 TKI 反應佳，可考慮雙藥策略（抗體+TKI 或 TKI+化療）。
• L858R → 單藥效果較弱，臨床上更傾向 Osimertinib + 化療。
Step 2：考慮年齡與耐受性
• <65 歲、體能佳 → 可承受副作用，雙藥策略更有價值。
• ≥65 歲或合併共病 → Osimertinib ± 化療。
在台灣第三代 EGFR TKI（Osimertinib）合併化療有健保給付，因此「財務負擔」這個選項上相對不是考慮重點；反而副作用、基因型、年齡才是關鍵。
🔄 決策流程
Step 1：確認基因型
• Exon 19 deletion → 對 TKI 反應佳，可考慮雙藥策略（抗體+TKI 或 TKI+化療）。
• L858R → 單藥效果較弱，臨床上更傾向 Osimertinib + 化療。
Step 2：考慮年齡與耐受性
• <65 歲、體能佳 → 可承受副作用，雙藥策略更有價值。
• ≥65 歲或合併共病 → Osimertinib ± 化療。
November 3, 2025 at 1:12 PM
肺腺癌EGFR突變的決策流程
在台灣第三代 EGFR TKI（Osimertinib）合併化療有健保給付，因此「財務負擔」這個選項上相對不是考慮重點；反而副作用、基因型、年齡才是關鍵。
🔄 決策流程
Step 1：確認基因型
• Exon 19 deletion → 對 TKI 反應佳，可考慮雙藥策略（抗體+TKI 或 TKI+化療）。
• L858R → 單藥效果較弱，臨床上更傾向 Osimertinib + 化療。
Step 2：考慮年齡與耐受性
• <65 歲、體能佳 → 可承受副作用，雙藥策略更有價值。
• ≥65 歲或合併共病 → Osimertinib ± 化療。
在台灣第三代 EGFR TKI（Osimertinib）合併化療有健保給付，因此「財務負擔」這個選項上相對不是考慮重點；反而副作用、基因型、年齡才是關鍵。
🔄 決策流程
Step 1：確認基因型
• Exon 19 deletion → 對 TKI 反應佳，可考慮雙藥策略（抗體+TKI 或 TKI+化療）。
• L858R → 單藥效果較弱，臨床上更傾向 Osimertinib + 化療。
Step 2：考慮年齡與耐受性
• <65 歲、體能佳 → 可承受副作用，雙藥策略更有價值。
• ≥65 歲或合併共病 → Osimertinib ± 化療。
Osimertinib retreatment may offer renewed disease control for select patients with advanced EGFR-mutated non-small cell lung cancer, according to new data from Fred Hutchinson Cancer Center. #lungcancer
www.sciencedirect.com/science/arti...
www.sciencedirect.com/science/arti...
Osimertinib Retreatment for Patients with Advanced EGFR-mutated Non-Small Cell Lung Cancer
Further research is needed to identify biomarkers of sensitivity and to optimize patient selection for osimertinib retreatment following interval chemotherapy.
www.sciencedirect.com
November 1, 2025 at 2:02 PM
Osimertinib retreatment may offer renewed disease control for select patients with advanced EGFR-mutated non-small cell lung cancer, according to new data from Fred Hutchinson Cancer Center. #lungcancer
www.sciencedirect.com/science/arti...
www.sciencedirect.com/science/arti...
Second-line therapy following osimertinib in metastatic EGFR-mutated non-small cell lung cancer at an academic medical center https://www.medrxiv.org/content/10.1101/2025.10.29.25339070v1
October 31, 2025 at 9:27 PM
Second-line therapy following osimertinib in metastatic EGFR-mutated non-small cell lung cancer at an academic medical center https://www.medrxiv.org/content/10.1101/2025.10.29.25339070v1
A Yale study finds the protein #METTL7A triggers early resistance to #osimertinib by reshaping DNA architecture. Targeting METTL7A could help block resistance before it starts. #lungcancer #adenocarcinoma
➡️ yalecancercenter.org/news-article...
➡️ yalecancercenter.org/news-article...
Yale Study Sheds Light on Cellular Resistance to Osimertinib in Adenocarcinoma
Some lung cancers manage to overcome a targeted drug therapy despite it showing initial success. Yale researchers have now discovered a molecular-level
yalecancercenter.org
October 31, 2025 at 3:56 PM
A Yale study finds the protein #METTL7A triggers early resistance to #osimertinib by reshaping DNA architecture. Targeting METTL7A could help block resistance before it starts. #lungcancer #adenocarcinoma
➡️ yalecancercenter.org/news-article...
➡️ yalecancercenter.org/news-article...
Real-world outcomes of second-line carboplatin plus pemetrexed after first-line osimertinib in EGFR-mutant advanced NSCLC: An international multicentre cohort study www.lungcancerjournal.info/article/S016... @velindrecc.bsky.social #lungcancer
Real-world outcomes of second-line carboplatin plus pemetrexed after first-line osimertinib in EGFR-mutant advanced NSCLC: An international multicentre cohort study
The third-generation epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor
(TKI) osimertinib became the first-line standard of care for patients with EGFR-mutant
advanced non-small cell lu...
www.lungcancerjournal.info
October 31, 2025 at 12:08 PM
Real-world outcomes of second-line carboplatin plus pemetrexed after first-line osimertinib in EGFR-mutant advanced NSCLC: An international multicentre cohort study www.lungcancerjournal.info/article/S016... @velindrecc.bsky.social #lungcancer
Osimertinib Plus Chemo Outperforms Single-Agent Osimertinib Regardless of Prognostic Factors in EGFR+ #NSCLC @danafarber.bsky.social #oncology #lungcancer
www.onclive.com/view/osimert...
www.onclive.com/view/osimert...
Osimertinib Plus Chemo Outperforms Single-Agent Osimertinib Regardless of Prognostic Factors in EGFR+ NSCLC | OncLive
Pasi A. Jänne, MD, PhD, shares data confirming an OS benefit with osimertinib plus chemotherapy regardless of baseline prognostic factors in EGFR-mutant NSCLC.
www.onclive.com
October 29, 2025 at 2:18 PM
Osimertinib Plus Chemo Outperforms Single-Agent Osimertinib Regardless of Prognostic Factors in EGFR+ #NSCLC @danafarber.bsky.social #oncology #lungcancer
www.onclive.com/view/osimert...
www.onclive.com/view/osimert...
Thomas Jefferson University Hospital is now enrolling patients in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. Learn more: bit.ly/pre1702-study
October 29, 2025 at 2:00 PM
Thomas Jefferson University Hospital is now enrolling patients in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. Learn more: bit.ly/pre1702-study
Su studio Flaura 2: 'Chemioterapia più osimertinib una delle novità più importanti per pazienti spesso con metastasi'
Tumore al polmone con Egfr mutato, oncologa: "Sopravvivenza a 4 anni con cura combinata"
ebx.sh
October 28, 2025 at 12:54 AM
Su studio Flaura 2: 'Chemioterapia più osimertinib una delle novità più importanti per pazienti spesso con metastasi'
Actinium's ATNM-400 Shows Promise Against Lung Cancer, Outperforming Leading EGFR Mutant Therapies#USA#New_York#Actinium#ATNM-400#Osimertinib
Actinium's ATNM-400 Shows Promise Against Lung Cancer, Outperforming Leading EGFR Mutant Therapies
Actinium Pharmaceuticals presents groundbreaking data on ATNM-400, showing it outperforms current EGFR mutant therapies in lung cancer, showcasing its potential in future treatments.
third-news.com
October 27, 2025 at 11:10 AM
Actinium's ATNM-400 Shows Promise Against Lung Cancer, Outperforming Leading EGFR Mutant Therapies#USA#New_York#Actinium#ATNM-400#Osimertinib
Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non–Small Cell Lung Cancer scientiasalut.gencat.cat/handle/11351... #ScientiaVH
Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non–Small Cell Lung Cancer
scientiasalut.gencat.cat
October 22, 2025 at 10:59 AM
Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non–Small Cell Lung Cancer scientiasalut.gencat.cat/handle/11351... #ScientiaVH
New front-line strategy: Combining osimertinib with chemotherapy in EGFR-mutated advanced NSCLC achieved a median overall survival of 47.5 months versus 37.6 months with osimertinib alone, a 23% reduced risk of death.
www.emjreviews.com/en-us/amj/re...
#AMJRespiratory #LungCancer
www.emjreviews.com/en-us/amj/re...
#AMJRespiratory #LungCancer
Osimertinib Plus Chemo Extends Survival in EGFR-Mutated NSCLC
In EGFR-mutated advanced NSCLC, first line osimertinib plus platinum-pemetrexed prolonged overall survival versus monotherapy, with higher grade 3 or greater adverse events reported.
www.emjreviews.com
October 21, 2025 at 1:28 PM
New front-line strategy: Combining osimertinib with chemotherapy in EGFR-mutated advanced NSCLC achieved a median overall survival of 47.5 months versus 37.6 months with osimertinib alone, a 23% reduced risk of death.
www.emjreviews.com/en-us/amj/re...
#AMJRespiratory #LungCancer
www.emjreviews.com/en-us/amj/re...
#AMJRespiratory #LungCancer
From Next-Generation HER2 TKIs to Perioperative Osimertinib Updates at ESMO 2025 - Narjust Florez
@narjustflorezmd.bsky.social @myesmo.bsky.social
oncodaily.com/voices/narju...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ESMO #ESMO25 #ESMO2025
@narjustflorezmd.bsky.social @myesmo.bsky.social
oncodaily.com/voices/narju...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ESMO #ESMO25 #ESMO2025
Narjust Florez: From Next-Generation HER2 TKIs to Perioperative Osimertinib Updates at ESMO 2025 - OncoDaily
Narjust Florez: From Next-Generation HER2 TKIs to Perioperative Osimertinib Updates at ESMO 2025 / cancer, ESMO, ESMO 2025, ESMO 2025 Congress, ESMO2025,
oncodaily.com
October 18, 2025 at 2:45 PM
From Next-Generation HER2 TKIs to Perioperative Osimertinib Updates at ESMO 2025 - Narjust Florez
@narjustflorezmd.bsky.social @myesmo.bsky.social
oncodaily.com/voices/narju...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ESMO #ESMO25 #ESMO2025
@narjustflorezmd.bsky.social @myesmo.bsky.social
oncodaily.com/voices/narju...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ESMO #ESMO25 #ESMO2025
I was delightedly surprised when my wonderful oncologist told me he had discussed with InovaSchar Cancer Institute
tumor board, & surgery was now a possibility. I asked since osimertinib is working so well, what's the benefit of having surgery? He said removing the site of my original tumor...
tumor board, & surgery was now a possibility. I asked since osimertinib is working so well, what's the benefit of having surgery? He said removing the site of my original tumor...
October 18, 2025 at 1:58 PM
I was delightedly surprised when my wonderful oncologist told me he had discussed with InovaSchar Cancer Institute
tumor board, & surgery was now a possibility. I asked since osimertinib is working so well, what's the benefit of having surgery? He said removing the site of my original tumor...
tumor board, & surgery was now a possibility. I asked since osimertinib is working so well, what's the benefit of having surgery? He said removing the site of my original tumor...
You'll remember since I had cancerous tumors and lymph nodes in both lungs, I expected to take 1-pill-a-day targeted therapy until it stopped working, which is common. But after 4 months, osimertinib cleared all but the tiniest remnants of my cancer in both lungs...
October 18, 2025 at 1:57 PM
You'll remember since I had cancerous tumors and lymph nodes in both lungs, I expected to take 1-pill-a-day targeted therapy until it stopped working, which is common. But after 4 months, osimertinib cleared all but the tiniest remnants of my cancer in both lungs...
✨#ESMO25✨
🚨BREAKING: Phase 3 Data!
📈 Osimertinib + chemotherapy significantly improved overall survival vs. Osimertinib alone in patients with EGFR-mutated advanced NSCLC.
✅ Reinforces its potential as a new first-line standard of care.
🔗 Read more: bit.ly/ONCOnews18O-1
🚨BREAKING: Phase 3 Data!
📈 Osimertinib + chemotherapy significantly improved overall survival vs. Osimertinib alone in patients with EGFR-mutated advanced NSCLC.
✅ Reinforces its potential as a new first-line standard of care.
🔗 Read more: bit.ly/ONCOnews18O-1
October 18, 2025 at 9:51 AM
✨#ESMO25✨
🚨BREAKING: Phase 3 Data!
📈 Osimertinib + chemotherapy significantly improved overall survival vs. Osimertinib alone in patients with EGFR-mutated advanced NSCLC.
✅ Reinforces its potential as a new first-line standard of care.
🔗 Read more: bit.ly/ONCOnews18O-1
🚨BREAKING: Phase 3 Data!
📈 Osimertinib + chemotherapy significantly improved overall survival vs. Osimertinib alone in patients with EGFR-mutated advanced NSCLC.
✅ Reinforces its potential as a new first-line standard of care.
🔗 Read more: bit.ly/ONCOnews18O-1
Osimertinib Plus Chemo Demonstrates OS Benefit in EGFR+ NSCLC With Poor Prognostic Factors @danafarber.bsky.social @myesmo.bsky.social #ESMO2025 #lcsm #oncology
www.onclive.com/view/osimert...
www.onclive.com/view/osimert...
Osimertinib Plus Chemo Demonstrates OS Benefit in EGFR+ NSCLC With Poor Prognostic Factors | OncLive
Osimertinib plus chemotherapy improved OS vs osimertinib alone in EGFR-mutated advanced non–small lung cancer, irrespective of poor prognostic factors.
www.onclive.com
October 17, 2025 at 8:46 PM
Osimertinib Plus Chemo Demonstrates OS Benefit in EGFR+ NSCLC With Poor Prognostic Factors @danafarber.bsky.social @myesmo.bsky.social #ESMO2025 #lcsm #oncology
www.onclive.com/view/osimert...
www.onclive.com/view/osimert...
👇NorthStar trial - #ESMO highlight 17.10.
🧠 LCT improved PFS across subgroups
🌐 Even with >3 mets (20.7 vs 15.9 mo)
🧬 EGFR ex19del: 39.8 vs 22.8 mo
🔬 L858Rmut: 19.1 vs 11.0 mo
💪 Comprehensive vs partial LCT: 33.1 vs 15.1 mo
dailyreporter.esmo.org
@myesmo.bsky.social @astro-org.bsky.social
🧠 LCT improved PFS across subgroups
🌐 Even with >3 mets (20.7 vs 15.9 mo)
🧬 EGFR ex19del: 39.8 vs 22.8 mo
🔬 L858Rmut: 19.1 vs 11.0 mo
💪 Comprehensive vs partial LCT: 33.1 vs 15.1 mo
dailyreporter.esmo.org
@myesmo.bsky.social @astro-org.bsky.social
October 17, 2025 at 8:28 PM
👇NorthStar trial - #ESMO highlight 17.10.
🧠 LCT improved PFS across subgroups
🌐 Even with >3 mets (20.7 vs 15.9 mo)
🧬 EGFR ex19del: 39.8 vs 22.8 mo
🔬 L858Rmut: 19.1 vs 11.0 mo
💪 Comprehensive vs partial LCT: 33.1 vs 15.1 mo
dailyreporter.esmo.org
@myesmo.bsky.social @astro-org.bsky.social
🧠 LCT improved PFS across subgroups
🌐 Even with >3 mets (20.7 vs 15.9 mo)
🧬 EGFR ex19del: 39.8 vs 22.8 mo
🔬 L858Rmut: 19.1 vs 11.0 mo
💪 Comprehensive vs partial LCT: 33.1 vs 15.1 mo
dailyreporter.esmo.org
@myesmo.bsky.social @astro-org.bsky.social